Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

IND 194 - A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Relapsed Mantle Cell Lymphoma - was closed to accrual on May 6, 2014.